HIGHLIGHTS
- who: Menghua Wu from the (UNIVERSITY) have published the paper: Camrelizumab for cancers in patients living with HIV: one-single center experience, in the Journal: (JOURNAL) of December/10,/2021
- what: The aim was to evaluate the safety of the anti-PD-1 antibody camrelizumab in people living with HIV (PLWH); the secondary objective was to evaluate tumor response. u00adCD4+ T-cell count greater than or equal to 100 cells/u00b5L were treated with camrelizumab in daily practice. Although this study demonstrated camrelizumab had a clinical benefit in PLWH with several cancers, this study did . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.